Adipose-derived cellular therapies in solid organ and vascularized-composite allotransplantation

Stivers, Katlin B; Beare, Jason E.; Chilton, Paula M.; Williams, Stuart K.; Kaufman, Christina L.; Hoying, James B.

doi:10.1097/mot.0000000000000452

Cited by 16 publications

(12 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASCs are primarily mesodermal, but some are of neural crest (ectodermal) origin [33], and have the potential to differentiate into at least adipogenic, chondrogenic, and osteogenic cells [1, 2]. Additionally, ASCs have the ability to reduce inflammation, mediated primarily via paracrine effects [6, 7, 9, 34, 35]. Both SVF and ASCs are currently utilised in clinics, but selecting between these two should be based on the particular disease application.…”

Section: Adipose Stromal/stem Cellsmentioning

confidence: 99%

Perspectives for Clinical Translation of Adipose Stromal/Stem Cells

Patrikoski

Mannerström

Miettinen

2019

Stem Cells International

View full text Add to dashboard Cite

Adipose stromal/stem cells (ASCs) are an ideal cell type for regenerative medicine applications, as they can easily be harvested from adipose tissue in large quantities. ASCs have excellent proliferation, differentiation, and immunoregulatory capacities that have been demonstrated in numerous studies. Great interest and investment have been placed in efforts to exploit the allogeneic use and immunomodulatory and anti-inflammatory effects of ASCs. However, bridging the gap betweenin vitroandin vivostudies and moving into clinical practice remain a challenge. For the clinical translation of ASCs, several issues must be considered, including how to characterise such a heterogenic cell population and how to ensure their safety and efficacy. This review explores the different phases ofin vitroand preclinical ASC characterisation and describes the development of appropriate potency assays. In addition, good manufacturing practice requirements are discussed, and cell-based medicinal products holding marketing authorisation in the European Union are reviewed. Moreover, the current status of clinical trials applying ASCs and the patent landscape in the field of ASC research are presented. Overall, this review highlights the applicability of ASCs for clinical cell therapies and discusses their potential.

show abstract

Section: Adipose Stromal/stem Cellsmentioning

confidence: 99%

Perspectives for Clinical Translation of Adipose Stromal/Stem Cells

Patrikoski

Mannerström

Miettinen

2019

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…However, these methods are expensive, time-consuming, and require specific Good Manufacturing Practice (GMP) facilities. Therefore, it is unlikely that they can be used in the peri-operative setting of a deceased donor KT [ 43 ]. Allogenic non-donor derived ASCs represent an intriguing option as off-the-shelf cellular products.…”

Section: Harvesting Proceduresmentioning

confidence: 99%

“…ASCs-based therapies have already been used to treat autoimmune disorders including systemic sclerosis, Crohn’s disease, systemic lupus erythematosus, and graft-versus-host disease [ 42 ]. Encouraging results have also been observed in pre-clinical and clinical models of renal allograft IRI and rejection [ 43 , 44 ]. However, the relatively small number of studies available and their methodological limitations do not allow conclusions to be drawn regarding ASCs efficacy and safety.…”

Section: Introductionmentioning

confidence: 99%

Adipose-Derived Stem/Stromal Cells in Kidney Transplantation: Status Quo and Future Perspectives

Storti

Favi

Albanesi

et al. 2021

IJMS

View full text Add to dashboard Cite

Kidney transplantation (KT) is the gold standard treatment of end-stage renal disease. Despite progressive advances in organ preservation, surgical technique, intensive care, and immunosuppression, long-term allograft survival has not significantly improved. Among the many peri-operative complications that can jeopardize transplant outcomes, ischemia–reperfusion injury (IRI) deserves special consideration as it is associated with delayed graft function, acute rejection, and premature transplant loss. Over the years, several strategies have been proposed to mitigate the impact of IRI and favor tolerance, with rather disappointing results. There is mounting evidence that adipose stem/stromal cells (ASCs) possess specific characteristics that could help prevent, reduce, or reverse IRI. Immunomodulating and tolerogenic properties have also been suggested, thus leading to the development of ASC-based prophylactic and therapeutic strategies in pre-clinical and clinical models of renal IRI and allograft rejection. ASCs are copious, easy to harvest, and readily expandable in culture. Furthermore, ASCs can secrete extracellular vesicles (EV) which may act as powerful mediators of tissue repair and tolerance. In the present review, we discuss the current knowledge on the mechanisms of action and therapeutic opportunities offered by ASCs and ASC-derived EVs in the KT setting. Most relevant pre-clinical and clinical studies as well as actual limitations and future perspective are highlighted.

show abstract

“…Human adipose-derived mesenchymal stem cells (hAdMSC) are known to have immunomodulatory properties. Their use in allograft transplantations was previously reported [ 63 ]. Interestingly, several animal models have shown promising results using hAdMSC in various autoimmune diseases.…”

Section: Future Perspectivementioning

confidence: 99%

Autoimmune Inner Ear Disease: Immune Biomarkers, Audiovestibular Aspects, and Therapeutic Modalities of Cogan’s Syndrome

Shamriz

Tal

Gross

2018

Journal of Immunology Research

View full text Add to dashboard Cite

Cogan's syndrome (CS) is a rare autoimmune disorder characterized by audiovestibular dysfunction and ocular inflammation. Currently, there is no specific serum autoantibody used in the diagnostic workup of CS. Treatment is based on immunosuppressive agents, mainly corticosteroids as first-line choice. Recently, novel therapeutic modalities in CS have emerged. These include tumor necrosis factor-α inhibitors and other biologicals. Despite medical treatment, hearing loss may progress to irreversible bilateral profound SNHL in approximately half of CS patients resulting in candidacy for cochlear implantation (CI). Due to the inflammatory nature of the disease that is causing endosteal reaction with partial obliteration or complete neoossification of the intracochlear ducts, early CI is recommended. CI provides excellent and stable hearing rehabilitation with high score of word and sentence recognition. In this review, we will discuss different aspects of CS including clinical presentation, diagnosis, treatment, and future directives.

show abstract

Adipose-derived cellular therapies in solid organ and vascularized-composite allotransplantation

Cited by 16 publications

References 106 publications

Perspectives for Clinical Translation of Adipose Stromal/Stem Cells

Perspectives for Clinical Translation of Adipose Stromal/Stem Cells

Adipose-Derived Stem/Stromal Cells in Kidney Transplantation: Status Quo and Future Perspectives

Autoimmune Inner Ear Disease: Immune Biomarkers, Audiovestibular Aspects, and Therapeutic Modalities of Cogan’s Syndrome

Contact Info

Product

Resources

About